Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2023 | Bispecific antibodies for R/R aggressive B-cell lymphomas

Paolo Strati • 8 Sep 2023

SOHO 2023

B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Epcoritamab Glofitamab

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the promise of CD20xCD3 bispecific antibodies, such as glofitamab and epcoritamab, in patients with relapsed/refractory (R/R) aggressive B-cell lymphomas, particularly those who relapse after CAR-T therapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

BTK inhibitors in the treatment of DLBCL: trials investigating these agents

Paolo Strati • 10 Dec 2023

Updates on the Smart Stop trial: the potential for a chemo-free regimen in the frontline for DLBCL

Paolo Strati • 10 Dec 2023

Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL

Paolo Strati • 10 Dec 2023

Autologous SIRPα- low macrophages (SIRPant-M) enhance immune anti-tumor activity in R/R NHL

Paolo Strati • 10 Dec 2023

Related Videos

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024